Treatment of brain disorders of the striatum
OwnerRobert C. Malenka, Anatol Kreitzerinventors
Life of this patent
Estimating the term…
Abstract
Regulation of striatal indirect pathway endocannabinoid-mediated long-term depression (eCB-LTD) is used to improve motor deficits of striatal-based brain disorders. In such treatment, a dopamine D2 receptor agonist is administered in conjunction with an inhibitor of endocannabinoid degradation. In some embodiments, the inhibitor of endocannabinoid degradation is a fatty acid amine hydrolase inhibitor, or a monoacylglycerol lipase antagonist. The combination provides for a synergistic effect, with improved therapeutic effects. Also provided are kits and systems for practicing the subject methods, as well as methods of use of agents identified in the screening method of the invention.
Claims7
A method of treating a subject for Parkinson's disease in a subject, said method comprising:
- administering to said subject a combination of drugs, said combination comprising
- (a) a D2 receptor agonist;
- and
- (b) an inhibitor of endocannabinoid degradation.
A method of identifying compounds for the treatment of brain disorders of the striatum, said method comprising:
- assessing the effectiveness of a candidate compound on indirect pathway eCB-LTD in vitro.
Dependencies are inferred from the claim text.